(Q53599930)

English

The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25707611

The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density. (English)

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25707611

phase II clinical trial

0 references

author name string

Christopher P Recknor

1

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25707611

Robert R Recker

2

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25707611

Charles T Benson

3

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25707611

Deborah A Robins

4

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25707611

Alan Y Chiang

5

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25707611

Jahangir Alam

6

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25707611

Leijun Hu

7

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25707611

Toshio Matsumoto

8

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25707611

Hideaki Sowa

9

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25707611

John H Sloan

10

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25707611

Robert J Konrad

11

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25707611

Bruce H Mitlak

12

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25707611

Adrien A Sipos

13

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25707611

publication date

11 June 2015

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25707611

Journal of Bone and Mineral Research

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25707611

30

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25707611

9

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25707611

1717-1725

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25707611

Public health impact of osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2489

21 January 2018

Clinician's Guide to Prevention and Treatment of Osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2489

21 January 2018

BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures.

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2489

21 January 2018

The global burden attributable to low bone mineral density.

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2489

21 January 2018

Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2489

21 January 2018

Osteoporosis and fragility fractures: Vertebral fractures.

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2489

21 January 2018

The impact of nonhip nonvertebral fractures in elderly women and men.

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2489

21 January 2018

SOST/sclerostin, an osteocyte-derived negative regulator of bone formation

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2489

21 January 2018

Bone biology and anabolic therapies for bone: current status and future prospects

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2489

21 January 2018

Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2489

21 January 2018

A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2489

21 January 2018

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2489

21 January 2018

Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2489

21 January 2018

Bone's mechanostat: A 2003 update

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2489

21 January 2018

Recent progress in osteocyte research

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2489

21 January 2018

Osteocyte control of bone remodeling: is sclerostin a key molecular coordinator of the balanced bone resorption-formation cycles?

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2489

21 January 2018

Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2489

21 January 2018

Theoretical analysis of interplay of therapeutic protein drug and circulating soluble target: temporal profiles of 'free' and 'total' drug and target

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2489

21 January 2018

Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets

1 reference

https://api.crossref.org/works/10.1002%2FJBMR.2489

21 January 2018

Identifiers

10.1002/JBMR.2489

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25707611

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/25707611

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53599930&oldid=879236640"